We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Low-Cost, Simple-to-Use, Ultrafast Point-of-Care COVID-19 Test to Provide RT PCR Results in 8 Minutes

By LabMedica International staff writers
Posted on 09 Oct 2020
A new low-cost, simple-to-use, ultrafast point-of-care test for COVID-19 aims to provide reverse transcription polymerase chain reaction (RT PCR) results in just eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

The promising new COVID-19 rapid-testing technology platform has been developed by Rover Diagnostics (New York, NY, USA) and Columbia Engineering (New York, NY, USA). More...
Rover’s ultrafast, portable PCR technology is based on two breakthroughs in science and engineering and it meets all the conditions for successful point-of-care PCR. First, it uses microfluidic sample preparation developed by Prof. Sam Sia’s lab at Columbia University’s Dept. of Bioengineering. This technology allows Rover to eliminate expensive, complex sample prep equipment in favor of a small, disposable chip.

Secondly, the platform uses a new approach to thermal cycling that bypasses the standard Peltier device which requires 40-60 minutes for amplification. Instead of radiant heat coming from outside the vial or well, the platform use photothermal gold nanoparticles to generate heat from inside. The result is thermal cycling that is 10x faster and uses 100x less energy than is possible today. Rover aims to combine these two technologies into an easy-to-use, sample-to-answer instrument. Furthermore, Rover will integrate HIPAA-compliant cloud access to allow for instant notification and large-scale data analysis. Rover’s COVID-19 rapid-testing technology platform has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies.

“We were determined to develop a testing platform for all kinds of viruses that is cheap, reliable, and accessible to everyone,” said Sia, an innovator in point-of-care blood tests, wearable sensors, and implantable devices. “With Rover, we can now perform thermal cycling, which is the backbone of high-performing DNA and RNA testing, several times faster.”

“We are expanding our testing of clinical samples and bringing together additional resources and expertise to finalize the design and speed to manufacturing. The NIH RADx initiative is accelerating our progress to bring the fast PCR platform to the widest possible good,” added Sia.

Related Links:
Rover Diagnostics
Columbia Engineering



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nucleic Acid Isolation Kit
MagMAX™ Viral/Pathogen Ultra Nucleic Acid Isolation Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.